WATCHMAN FLX data
Procedural adverse events1
Procedural success rate2
Complete Closure at 12 months1
The SURPASS analysis of the NCDR-LAAO Registry™ includes the largest number of commercial WATCHMAN FLX patients to date. This data reinforces the outstanding safety of WATCHMAN FLX with 0.37% major procedural adverse event rate within 7 days or hospital discharge and 98% procedural success rate in > 16,000 real-world NVAF patients.3
How we can help you and your program
HAWKEYE is an online solution to help you facilitate LAACpatient workflow. HAWKEYE helps you understand programperformance and patient outcomes, making it easier tooptimize operational efficiencies and streamline patientcoordination.
Healthcare Solutions Team
Healthcare Solutions is a team of former hospital administrators who help LAAC programs identify opportunities to accelerate program success and development. The Calibration Program identifies and tailor solutions to optimize LAAC programs.
- Kar S, et al. Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device: Results From the PINNACLE FLX Trial. Circulation. 2021;143:1754-1762.
- Late Breaking Clinical Trial at CRT 2022, Presented by Dr. Samir Kapadia
- Kar. S, Circulation, 2021